This is a pre-revenue clinical-stage biotech — the earnings report itself is routine and non-directional. The stock will trade on pipeline catalysts: Phase 2b high-dose ribupatide data in 2027 and Phase 3 obesity data in 2028. Monitor upcoming ADA 2026 presentations (June 5-8) for detailed data on ribupatide oral and KAI-4729, which could provide near-term volatility.
Price Chart
Executive Summary
Kailera Therapeutics reported Q1 2026 net loss of $78.9M vs $18.0M in Q1 2025, with R&D expenses surging to $70.9M from $10.1M as it initiated multiple late-stage obesity trials. The company has $581.9M in cash (plus $718.8M IPO gross proceeds) funding operations into mid-2028, but the pre-revenue clinical-stage biotech has no revenue and widening losses — the stock's move hinges on pipeline milestones (Phase 3 ribupatide data in 2028, Phase 2b high-dose data in 2027) rather than financial results.
Key Facts
- Net loss of $78.9M in Q1 2026 vs $18.0M in Q1 2025
- R&D expenses $70.9M vs $10.1M year-over-year
- Cash, cash equivalents and marketable securities of $581.9M as of March 31, 2026
- Closed $718.8M IPO of 44,921,875 shares at $16.00 per share in April 2026
- Initiated global Phase 3 KaiNETIC program for ribupatide injection with data anticipated in 2028
- Positive topline data from partner Hengrui's Phase 3 T2D trial of KAI-7535 and Phase 1 trial of KAI-4729
- No revenue reported — pre-revenue clinical-stage biotechnology company
Financial Impact
Net loss widened by $60.9M vs prior year; cash burn rate increased significantly with R&D ramp
Risk Factors
- Clinical trial failure risk across all four programs
- Cash burn rate accelerating — $581.9M may not cover operations beyond mid-2028 without additional financing
- Dependence on partner Hengrui for data generation and regulatory submissions in China
- Highly competitive obesity market with multiple approved GLP-1 therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301439 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 22d ago | 3 | $14.91 $12.92 | ▼ −13.35% | ▼ −12.85% | $10.39 (−30.32%) |
Aug 12, 2026 7w ago | 8-K | $17.97 $17.47 | ▼ −2.78% | ▼ −0.82% | $10.39 (−42.18%) |
Jul 31, 2026 9w ago | Court Ruling | $16.94 $18.66 | ▲ +10.15% | ▲ +6.64% | $10.39 (−38.67%) |
Jul 24, 2026 10w ago | Court Ruling | $17.69 $17.05 | ▼ −3.62% | ▼ −3.99% | $10.39 (−41.27%) |
Jun 5, 2026 16w ago | Press Release | $19.70 $19.67 | ▼ −0.15% | ▼ −2.26% | $10.39 (−47.26%) |
May 26, 2026 18w ago | 8-K | $21.91 $22.38 | ▲ +2.15% | ▲ +1.68% | $10.39 (−52.58%) |
May 26, 2026 18w ago | Press Release | $21.91 $22.59 | ▲ +3.10% | ▲ +1.90% | $10.39 (−52.58%) |
May 13, 2026 20w ago | Press Release | $21.11 $19.62 | ▼ −7.06% | ▼ −5.90% | $10.39 (−50.78%) |
Apr 20, 2026 23w ago | 8-K | $25.22 $23.82 | ▼ −5.55% | ▼ −6.63% | $10.39 (−58.80%) |
Apr 20, 2026 23w ago | Insider Cluster | $24.61 $23.51 | ▼ −4.47% | ▼ −5.38% | $10.39 (−57.78%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access